Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Immunic Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IMUX
Nasdaq
8731
https://imux.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Immunic Inc
With 44% ownership, Immunic, Inc. (NASDAQ:IMUX) has piqued the interest of hedge funds investors
- Apr 4th, 2024 11:53 am
Immunic to Host MS R&D Day and Participate in Investor Conferences in April
- Apr 4th, 2024 10:30 am
Immunic CMO discusses complexities of multiple sclerosis to mark MS Awareness Month
- Mar 21st, 2024 4:14 pm
Immunic secures key patent, boosting MS drug exclusivity and global IP strategy
- Mar 21st, 2024 3:37 pm
Immunic Receives Notice of Allowance for Composition-of-Matter Patent of a Specific Polymorph of Vidofludimus Calcium in the United States
- Mar 20th, 2024 10:30 am
Immunic to reveal promising MS treatment data in two poster presentations at ACTRIMS Forum 2024
- Mar 8th, 2024 11:53 am
Immunic to Participate in Investor and Scientific Conferences in March
- Mar 7th, 2024 11:30 am
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
- Feb 29th, 2024 11:30 am
Immunic Inc (IMUX) Reports Year-End 2023 Financial Results
- Feb 24th, 2024 2:02 am
Immunic, Inc. (NASDAQ:IMUX) Q4 2023 Earnings Call Transcript
- Feb 23rd, 2024 4:04 pm
Immunic reports successful 2023 and prepares for key 2025 milestones
- Feb 22nd, 2024 3:59 pm
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
- Feb 22nd, 2024 11:30 am
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
- Feb 15th, 2024 11:30 am
Immunic to Participate in Investor and Scientific Conferences in February
- Feb 1st, 2024 11:30 am
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
- Jan 5th, 2024 11:35 am
Immunic, Inc. Announces Private Placement of up to $240 Million
- Jan 5th, 2024 11:30 am
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
- Nov 21st, 2023 11:30 am
Immunic focusing on business development during Q4
- Nov 14th, 2023 6:25 pm
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
- Nov 14th, 2023 11:30 am
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
- Nov 7th, 2023 11:30 am
Scroll